Uses of Tachykinin Receptor 3 Inhibitors
NK3R inhibitors like fezolinetant and pavinetant address the lack of effective treatments for cancer-induced kidney damage by improving renal function and reducing tubular lesions, offering a promising therapeutic approach for chronic kidney disease.
Patent Information
- Application Number
- JP2024522581
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-10-18
- Filing Date
- 2022-10-13
- Publication Date
- 2024-11-06
AI Technical Summary
Current treatments for cancer-induced kidney damage and chronic kidney disease lack effective therapeutic options, with the etiology of cancer-induced kidney damage being unknown and no approved treatments by the U.S. Food and Drug Administration, necessitating the development of drugs that can protect renal function and treat renal impairment.
The use of NK3R inhibitors, such as fezolinetant and pavinetant, to treat chronic kidney disease and tumor-induced renal tubular injury by inhibiting tachykinin receptor 3 (NK3R), which has been shown to improve renal function and reduce kidney damage in various tumor models.
NK3R inhibitors significantly reverse tumor-induced renal tubular damage, improving kidney function and reducing ascites and renal tubular lesions in Drosophila and mouse models, demonstrating potential as effective agents for treating chronic kidney disease and renal impairment.
Smart Images

Figure 2024540881000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to a new use of a compound, specifically to a new use of a tachykinin receptor 3 (NK3R) inhibitor. [Background technology]
[0002] 1.1.Chronic Kidney Disease (CKD) Chronic kidney disease (CKD) has become a global public health issue. The prevalence of adult chronic kidney disease in China reached 11% in 2016, and the increasing rate of chronic kidney disease is expected to exceed 17% in the next 10 years. Chronic kidney disease refers to chronic structural and functional impairment of the kidney (history of kidney damage ≥ 3 months) caused by various causes. It includes renal tubular lesions, pathological damage leading to abnormal glomerular filtration rate (GFR), abnormal blood and urine composition, abnormal imaging results, and unexplained decline in GFR (< 60ml / min·1.73m 2 ) lasts for more than three months, it can be said to be chronic kidney disease. Chronic kidney disease is irreversible, and most kidney disease patients have to rely on long-term medication to slow the progression of the disease. As of 2016, the market size of kidney disease drugs in China was 28.74 billion yuan, and the global pharmaceutical market size was 151.98 billion US dollars. The main risk factors that can cause chronic kidney disease include high blood pressure, diabetes, cancer, aging, and pharmacological damage.
[0003] 1.2.Cancer and kidney disease Due to the occurrence of new cases and the increased survival of patients, the number of cancer patients worldwide has increased to nearly 9 million, of which 60% suffer from malignant tumors. It is the direct cause of death for almost a quarter of cancer patients. [1][4] is a tumor-induced complication that includes cancer-related kidney injury, which can include chronic kidney disease and acute kidney injury resulting from direct kidney damage by chemotherapy drugs, invasion and compression of the urinary system by tumors, and prerenal kidney injury due to systemic depletion. [5]Meanwhile, end-stage kidney disease (uremia) can cause metabolic and immune disorders in the body, which can lead to the occurrence or worsening of organ failure. In addition, complications of chronic kidney disease further reduce the survival rate of cancer patients. Therefore, it is necessary to rationally optimize the comprehensive treatment and management of cancer patients with kidney damage, and pay attention to protecting kidney function and treating kidney damage. However, since the cause of kidney damage caused by cancer is unknown, we can only rely mainly on palliative care. [2] Even the U.S. Food and Drug Administration has yet to approve a drug to treat the cancer complication. [3] Therefore, further research and development is needed to develop drugs to treat cancer-related kidney disease.
[0004] 2.NK3R inhibitors 2.1. Function and expression of NK3R NK3R (tachykinin receptor 3) is a G protein-coupled receptor that has been the subject of extensive research in the fields of development and reproduction. NK3R is expressed in a variety of mammalian tissues. In particular, NK3R expressed in the nervous system is known to be associated with various neurological disorders, including mood disorders, Alzheimer's disease, Parkinson's disease, and schizophrenia. [6] NK3R is also highly expressed in tissues such as the kidney and bladder, but its effects on the urinary system remain to be elucidated. We have discovered for the first time that NK3R is a key regulator mediating tumor-induced kidney dysfunction, and that inhibition of NK3R can significantly improve kidney function without affecting tumor growth.
[0005] 2.2. Information on small molecules that inhibit NK3R Fezorinetanant has the molecular formula C 16 H 15 FN 6 OS, a molecular weight of 358.4 g / mol, is an effective NK3R selective inhibitor having the structural formula shown in formula (I) below. In vitro tests showed that the inhibition constant Ki of the NK3R inhibitory effect was 25 nM and IC50 was 20 nM. Phase II clinical trials showed that it had a significant effect on improving hot flashes in postmenopausal women. [8] A phase 2 clinical trial for polycystic ovary syndrome is currently underway.
[0006] [ka]
[0007] Pavinetant has the molecular formula C 26 H 25 N 3 O 3 S, another potent NK3R selective inhibitor, has a molecular weight of 459.6 g / mol and a structural formula as shown in formula (II). The inhibitory activity IC50 in in vitro tests was found to be 7.1 μM and 19.8 μM in midazolam and testosterone tests, respectively, in the cytochrome P450-3A4 enzyme activity assay. In addition, Phase II clinical trials have shown that it significantly improves polycystic ovarian syndrome and hot flashes. [7] .
[0008] [ka]
[0009] However, the effects of NK3R inhibition by the above two inhibitors on renal function have not yet been reported. Summary of the Invention [Problem to be solved by the invention]
[0010] An object of the present invention is to provide a new use of an NK3R inhibitor. [Means for solving the problem]
[0011] Previous studies have shown that administration of these two inhibitors to tumor-bearing Drosophila and mouse models promotes urination, improves renal function, and reduces kidney damage and ascites formation. These results suggest that the NK3R inhibitors pavinetant and fezolinethant may be effective drugs for treating tumor-induced kidney damage.
[0012] According to one aspect of the present invention, there is provided a use of an NK3R inhibitor in the preparation of a medicament for use in the treatment of chronic kidney disease, the NK3R inhibitor having a structure as shown in formula (I) or formula (II).
[0013] In a preferred embodiment of the present invention, the NK3R inhibitor is used to treat chronic kidney disease, which is selected from the group consisting of glomerulonephritis, latent nephritis, pyelonephritis, allergic purpura nephritis, lupus erythematosus nephritis, gouty nephropathy, IgA nephropathy, nephrotic syndrome, membranous nephropathy, nephrotic syndrome, diabetic nephropathy, hypertensive nephropathy, and polycystic kidney disease.
[0014] According to another aspect of the present invention, there is provided a use of a tachykinin receptor 3 inhibitor in the preparation of a medicament for treating tumor-induced renal tubular injury or kidney disease, wherein the NK3R inhibitor has the structure shown in Formula (I) or Formula (II).
[0015] More preferably, the NK3R inhibitor according to the present invention is used for the treatment of renal damage in advanced stage tumors.
[0016] The present inventors have found that two NK3R inhibitors, namely fezolinethant and pavithant, can be used to reduce tumor-induced renal tubular damage.
[0017] Experiments with Drosophila have demonstrated that overexpression of the activated proto-oncogene yki in intestinal stem cells of Drosophila melanogaster can induce significant hyperglycemia and ascites. Feeding Drosophila melanogaster with diet supplemented with the NK3R inhibitors fezolinethant (100 μM) and pavithant (100 μM) for 6 days significantly reduced ascites and normalized blood glucose levels. C57BL / 6J-APCMin / + mice are a well-established model of intestinal adenoma. Further experiments revealed that NK3R was highly expressed in renal tubules. C57BL / 6J-APCMin / + mice began to show weight loss at 16 weeks of age and had approximately 30% reduced urine volume compared to normal C57BL / 6J mice. HE staining of the kidneys also revealed that the renal tubules were severely damaged. Intraperitoneal administration of the NK3R inhibitor fezolinethant (10 mg / kg / day) for 9 days significantly reversed renal tubular damage, including urinary volume and tubular dilatation, in C57BL / 6J-APCMin / + mice. MFC (mouse forestomach carcinoma) tumors were established in the peritoneal cavity of the mice. As the tumors grew, they could cause severe ascites and renal tubular damage in the mice. Experiments showed that 1.5 × 10 7 It was found that intraperitoneal injection of MFC tumor cells could induce significant ascites on the sixth day of the experiment, i.e., 24 hours after tumor cell injection. Administration of the NK3R inhibitor pavinetant (50 mg / kg / day) by intraperitoneal injection for five consecutive days could significantly suppress ascites formation and alleviate tubular lesions, mainly including tubular dilatation. Effect of the Invention
[0018] Thus, the NK3R inhibitors of the present invention can significantly reverse tumor-induced renal tubular damage, showing consistent results in various tumor models. [Brief description of the drawings]
[0019] [Figure 1]Effect of NK3R inhibitor on intestinal tumor-induced ascites in Drosophila. Panel A shows ascites phenotype and tumor morphology in Drosophila, Panel B shows blood glucose and triglyceride concentrations in Drosophila, and Panel C shows ascites ratio in Drosophila. Non is blank, F10 is fezolinethant 10 μM, F100 is fezolinethant 100 μM, P10 is pavithant 10 μM, and P100 is pavithant 100 μM. [Diagram 2] Immunohistochemistry reveals NK3R expression in mouse renal tubules. Kidneys from C57BL / 6 mice were treated with immunohistochemotherapy using antibodies ABclonalA7220 (left) and abcam ab124025 (right). [Diagram 3] Effect of NK3R inhibitor on renal damage caused by intestinal adenoma. Panel E shows the body weight change in C57BL / 6 and C57BL / 6J-APCMin / + mice, Panel F shows the urine output, and Panel G shows HE staining of longitudinal kidney sections. F10 means fezolinethant 10 mg / kg / day. [Figure 4] Effect of NK3R inhibitor on ascites and kidney damage caused by forestomach cancer cell tumors. Panel H shows the weight change of C57BL / 6 and MFC tumor mice, Panel I shows the amount of ascites in mice, Panel J shows the expression level of the renal tubule injury marker gene NGAL, and Panel K shows HE staining of longitudinal kidney sections. Pavi10 means 10 mg / kg / day of pavinetant, and Pavi50 means 50 mg / kg / day of pavinetant. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0020] Explanation of terms: Chronic kidney disease as referred to herein refers to the phenotype of chronic kidney disease, such as oliguria and ascites, in advanced stages in oncology patients. Tumor-induced kidney disease or renal tubule damage described herein refers to ascites, weight gain (mainly increased ascites), and renal tubule dilatation in MFC tumor mice, decreased urine volume and renal tubule dilatation in ApcMin / + mice, and renal tubule damage including ascites and decreased urine volume at physiological concentrations in patients, renal tubule dilatation, and changes in molecular markers of injury at the tissue level.
[0021] The present invention is illustrated in detail by the following description of preferred embodiments, but is not limited thereto.
[0022] manufacturer: NK3R Antibody 1: Abclonal, Catalog No. A7220 NK3R Antibody 2: Abcam, Catalog No. ab124025 Fezorinetant: MedChemExpress (MCE), catalog number HY-19632, 200 mg Pavinetant: MedChemExpress (MCE), Catalog No. HY-14432, 1g, customized
[0023] Experimental animals: Yki-activated Drosophila (derived directly from a cross of esg-GAL4, tub-GAL80TS, UAS-GFP, and UAS-yki.3SA in the lab; published in the literature, pubmed number 34407411) C57BL / 6J-APCMin / + mice (Gempharmatech, Cat. No. T001457, genotype B6 / JGpt-Apcem1Cin(Min) / Gpt) Control group: C57BL / 6J mice (Gempharmatech, Cat. No. N000013) MFC tumor cells (ProCell, Catalog No. CL-0156, 1x106 cells / T25 culture flask) Other substances were purchased commercially.
[0024] [Example 1] Effect of NK3R inhibitor on intestinal tumor-induced ascites in Drosophila Overexpression of the activated proto-oncogene yki in Drosophila intestinal stem cells can induce malignant proliferation of intestinal stem cells and subsequently tumor formation, which severely damages the secretory function of Malpighian tubules in Drosophila, preventing the circulating fluid in the hemolymph of Drosophila from being drained out of the body, resulting in a severe ascites phenotype. Test method: Gene expression was initiated at 29℃ to induce activated yki tumors (genotypes esg-Gal4, UAS-GFP, tub-Gal80TS / +, UAS-yki3SA / +) in the intestine of Drosophila melanogaster. Drosophila melanogaster were fed diets containing DMSO, fezolinethant (10μM, 100μM), or pavithant (10μM, 100μM) for 8 days, and compared with the control group (esg-Gal4, UAS-GFP, tub-Gal80TS / +), phenotypes were observed, changes in intestinal tumor growth and systemic glycolipids were detected, and ascites ratios were calculated. See Figure 1.
[0025] RESULTS:Both NK3R inhibitors at 100 μM could significantly inhibit ascites formation and restore blood glucose levels in Drosophila.
[0026] [Example 2] High expression of NK3R in mouse renal tubules Test method: Kidney sections were taken from 7-8 week old C57BL / 6J male mice, and immunohistochemistry was performed using two different NK3R antibodies (primary antibody dilution: ABclonalA7220, 1:200 and abcamAb124025, 1:200) to observe the expression of NK3R in the kidney. See Figure 2.
[0027] Results: NK3R was highly expressed in mouse renal tubules but not in glomeruli.
[0028] [Example 3] Effect of NK3R inhibitor on renal damage caused by intestinal adenoma C57BL / 6J-APCMin / + mice are a model of adult mammalian intestinal adenomas and are commonly used to study tumor-induced host attrition. C57BL / 6J-APCMin / + mice develop severe renal tubular damage during advanced stages of tumor development, resulting in a significant reduction in urine output compared to normal mice.
[0029] Test method: Male C57BL / 6J mice (control group) and C57BL / 6J-APCMin / + mice (experimental group), 7 mice per group, were fed under normal feeding conditions until 16 weeks of age. When the mice in the experimental group started to lose weight, they were administered fezolinethant (0, 10 mg / kg / day) by intraperitoneal injection for 9 consecutive days. Body weight and urine volume were measured, and the morphology of renal tubules was observed by staining the kidneys. See Figure 3.
[0030] Results: Intraperitoneal injection of the NK3R inhibitor fezolinethant (10 mg / kg / day) significantly rescued urinary output and renal tubular damage in C57BL / 6J-APCMin / + mice.
[0031] [Example 4] Effect of NK3R inhibitor on ascites and renal damage caused by forestomach cancer cells MFC tumors (mouse forestomach carcinoma) are common tumors that can cause ascites and colonize the peritoneal cavity of mice. As the tumors grow, they can cause severe ascites and renal tubular damage in mice.
[0032] Test method: Male C57BL / 6J mice aged 4-6 weeks were used. Experimental C57BL / 6J mice (6 mice per group) were intraperitoneally injected with 1.5×107 MFC tumor cells, and 24 hours later, the inhibitor pavinetant (0, 10, 50 mg / kg / day) was administered intraperitoneally. After 5 days of continuous administration, they were compared with the control C57BL / 6 mice (6 mice per group). Body weight, ascites, and urine volume were detected, while the kidneys were stained to observe the morphology of renal tubules. See Figure 4.
[0033] Results: The NK3R inhibitor pavinetant (50 mg / kg / day) significantly inhibited ascites formation and reduced tubular lesions.
[0034] References [1] ZHU X, CALLAHAN M F, GRUBER K A, et al. Melanocortin-4 receptor antagonist TCMCB07 ameliorates cancer- and chronic kidney disease-associated cachexia[J]. J Clin Invest, 2020,130(9): 4921-4934. [2] CUI Jiuwei, LI Wei, XU Hongxia, et al. Guidelines for the clinical diagnosis and treatment of tumor malignancy (2020) [J]. Chinese Journal of Clinical Oncology, 2021,48(08): 379-385. [3] ROELAND E J, BOHLKE K, BARACOS V E, et al. Management of Cancer Cachexia: ASCO Guideline[J]. J Clin Oncol, 2020,38(21): 2438-2453. [4] LAUNAY-VACHER V, JANUS N, DERAY G. Renal insufficiency and cancer treatments[J]. ESMO open, 2016,1(4): e91. [5] MALYSZKO J, TESAROVA P, CAPASSO G, et al. The link between kidney disease and cancer: complications and treatment[J]. Lancet, 2020,396(10246): 277-287. [6] ZHANG W, WANG Y, CHU Y. Tacr3 / NK3R: Beyond Their Roles in Reproduction[J]. ACS Chemical Neuroscience, 2020,11(19): 2935-2943. [7] GEORGE J T, KAKKAR R, MARSHALL J, et al. Neurokinin B Receptor Antagonism in Women With Polycystic Ovary Syndrome: A Randomized, Placebo-Controlled Trial[J]. The Journal of Clinical Endocrinology & Metabolism, 2016,101(11): 4313-4321. [8] FRASER G L, LEDERMAN S, WALDBAUM A, et al. A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause[J]. Menopause, 2020,27(4): 382-392.
Claims
1. 23. Use of a tachykinin receptor 3 inhibitor in the preparation of a medicament for the treatment of chronic kidney disease, wherein the tachykinin receptor 3 inhibitor has a structure as shown in formula (I) or formula (II). [Formula 1] [Case 2]
2. The use according to claim 1, wherein the chronic kidney disease is selected from the group consisting of glomerulonephritis, latent nephritis, pyelonephritis, allergic purpura nephritis, lupus erythematosus nephritis, gouty nephropathy, IgA nephropathy, nephrotic syndrome, membranous nephropathy, nephrotic syndrome, diabetic nephropathy, hypertensive nephropathy, and polycystic kidney disease.
3. 1. Use of a tachykinin receptor 3 inhibitor in the preparation of a medicament for the treatment of a disease, wherein the disease is tumor-induced renal tubular damage or kidney disease, and the tachykinin receptor 3 inhibitor has a structure as shown in Formula (I) or Formula (II). [C3] [C4]
4. The use according to claim 3, wherein the disease is renal damage in advanced stage tumors.
Citation Information
Patent Citations
Alkylsulphonamide quinolines
CN101370782A
Novel n-acyl-(3-substituted)-(8-substituted)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor-mediated disorders
CN105229008A
Diagnostics and therapeutics for diseases associated with tachykinin receptor 3 (TACR3)
WO2005100997A2
Prophylactic or therapeutic agent and medicinal composition for il-31-mediated disease
WO2020101017A1
